Precefi will be in Boston next week for the 10th Dermatology Drug Development Summit, November 3–5, 2026 at The Colonnade Boston. Marking its 10th anniversary, the summit brings together 90+ leaders from AbbVie, Galderma, Eli Lilly, Merck, Sun Pharma and the biotechs shaping the next generation of inflammatory skin disease therapies, spanning discovery, translational medicine, clinical development and commercialization.
Featured session
Precefi CEO & Co-Founder Richard Panico will present on behalf of Alphyn Biologics, Inc. on Wednesday, November 4 at 11:30 AM:
Moving Beyond Single-Target Therapies: Clinical Development Insights from a Multi-Target Platform in Atopic Dermatitis & Molluscum Contagiosum
- How multi-mechanistic therapeutics may address complex disease biology more effectively than conventional single-target approaches
- Pharmacokinetic, mechanistic and translational learnings supporting development across inflammatory and infectious dermatological conditions
- Phase 2 clinical development strategies and cross-indication insights to accelerate future applications of multi-target therapeutics
View the session on the summit website →
Meet us in Boston
If you’re attending, we’d welcome the chance to talk — dermatology, ophthalmology and aesthetics trials, our U.S. and Latin American site network, or the Appiell platform. To set up time in Boston, email Rich directly at rich@precefi.com.
